指南与共识皮肤肿瘤

欧洲光化性角化病、上皮性紫外线诱导发育不良与区域癌化诊疗预防跨学科共识指南

European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes).
指南 / 共识 · J Eur Acad Dermatol Venereol · 2024-03-07

欧洲多学科专家组基于当前文献与专家共识制定本指南,涵盖免疫功能正常及免疫抑制患者光化性角化病的流行病学、诊断、风险分层与治疗。光化性角化病是皮肤鳞状细胞癌的潜在前驱病变,在白色人种中最常见,常发生于紫外线诱导的癌化区域,因无法预测哪些病变会进展,通常建议治疗。诊断依靠临床检查,皮肤镜、共聚焦显微镜、光学相干断层扫描或线场共聚焦OCT可辅助鉴别,可疑或治疗抵抗病变需活检。治疗选择取决于患者和病变特征。

要点

  • 光化性角化病是皮肤鳞状细胞癌潜在前驱病变,通常建议治疗。
  • 诊断依靠临床检查,皮肤镜、共聚焦显微镜、OCT可辅助鉴别。
  • 多发病变建议区域癌化治疗,包括局部治疗和光动力疗法。

核心结论

  • 光化性角化病是皮肤鳞状细胞癌的潜在前驱病变,因无法预测哪些病变会进展,通常建议治疗。

研究设计与样本

  • 由欧洲皮肤肿瘤学会、欧洲皮肤病论坛、欧洲皮肤病与性病学会及欧洲医学专家联盟的多学科专家合作,基于当前文献和专家共识制定欧洲推荐。

主要发现

  • 光化性角化病在早期阶段即显示皮肤鳞状细胞癌的典型组织病理学和免疫组化特征,少数病例可发展为原位癌并变为浸润性。
  • 光化性角化病是白色人种中最常见的肿瘤,常发生于紫外线诱导的癌化区域内。

关键数值与推荐

  • 光化性角化病和区域癌化的诊断通过临床检查作出。
  • 皮肤镜、共聚焦显微镜、光学相干断层扫描或线场共聚焦OCT可帮助鉴别光化性角化病与其他皮肤肿瘤。
  • 临床和/或皮肤镜下可疑和/或治疗抵抗的病变需进行活检。
  • 单个非角化过度性病变可根据患者要求开始破坏性治疗或局部治疗。
  • 多发病变建议进行区域癌化治疗,包括局部治疗和光动力疗法。

临床怎么用

  • 对单个非角化过度性病变,可根据患者要求选择破坏性治疗或局部治疗。
  • 对多发病变,建议采用局部治疗和光动力疗法进行区域癌化治疗。
  • 建议高危患者采取防晒、自我检查及对既往受累皮肤区域重复区域癌化治疗等预防措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A collaboration of multidisciplinary experts from the European Association of Dermato-Oncology, the European Dermatology Forum, the European Academy of Dermatology and Venereology, and the European Union of Medical Specialists was formed to develop European recommendations on AK diagnosis and treatment, based on current literature and expert consensus. This guideline addresses the epidemiology, diagnostics, risk stratification and treatments in immunocompetent as well as immunosuppressed patients. Actinic keratoses (AK) are potential precursors of cutaneous squamous cell carcinoma (cSCC) and display typical histopathologic and immunohistochemical features of this malignancy in an early stage. They can develop into cSSC in situ and become invasive in a low percentage of cases. AK is the most frequent neoplasia in white populations, frequently occurring within a cancerous field induced by ultraviolet radiation. Since it cannot be predicted, which lesion will progress to cSCC and when treatment is usually recommended. The diagnosis of AK and field cancerization is made by clinical examination. Dermatoscopy, confocal microscopy, optical coherence tomography or line-field confocal-OCT can help in the differential diagnosis of AK and other skin neoplasms. A biopsy is indicated in clinically and/or dermatoscopically suspicious and/or treatment-refractory lesions. The choice of treatment depends on patients' and lesion characteristics. For single non-hyperkeratotic lesions, the treatment can be started upon patient's request with destructive treatments or topical treatments. For multiple lesions, field cancerization treatment is advised with topical treatments and photodynamic therapy. Preventive measures such as sun protection, self-examination and repeated field cancerization treatments of previously affected skin areas in high-risk patients are advised.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Kandolf L, Peris K, Malvehy J, et al. European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes). J Eur Acad Dermatol Venereol. 2024. PMID: 38451047. doi:10.1111/jdv.19897

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。